// App-Quantinova.ai

LBA-7 : Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC

Researchers

Presenter

  • A. Grothey

Principal Investigators

  • S. Kopetz

  • R. Yaeger

  • E. Van Cutsem

  • H. Wasan

  • J. Desai

  • F. Ciardiello

  • T. Yoshino

  • K. Maharry

  • J. Christy-Bittel

  • A. Gollerkeri

  • J. Tabernero

Medical Centers

  • West Cancer Center, University of Tennessee, Germantown, TN

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

  • Hammersmith Hospital, Division of Cancer, Imperial College London, London, United Kingdom

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Universita Della Campania "Luigi Vanvitelli", Napoli, Italy

  • National Cancer Center, EPOC, Chiba, Japan

  • Pfizer Inc, New York, NY

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Locations

  • United States

  • Belgium

  • United Kingdom

  • Australia

  • Italy

  • Japan

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • Carbohydrate antigen 19-9

  • Carcinoembryonic antigen

Drug/Treatment

  • Binimetinib

  • Encorafenib

  • Erbitux

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved